Sandoz’s Filgrastim Biosimilar Relies On Data Extrapolation
This article was originally published in The Pink Sheet Daily
Executive Summary
351(k) application seeks approval for full array of indications carried by Amgen’s Neupogen, which could give Sandoz product a competitive advantage over Teva’s marketed tbo-filgrastim, approved as traditional BLA.